SoftBank and Hanwha-backed biomanufacturer Zymergen floated at the top of its range in an upsized offering following over $870m in venture funding.

Zymergen, the US-based biomanufacturer backed by telecommunications and internet group SoftBank and conglomerate Hanwha, is going public today in a $500m initial public offering on the Nasdaq Global Select Market. The offering consists of just over 16.1 million shares, upsized from an initial allocation of 13.6 million and priced at the top of its $28…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.